Julian Harrison
Stock Analyst at BTIG
(4.97)
# 88
Out of 4,988 analysts
505
Total ratings
52.1%
Success rate
47.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Reiterated: Buy | $178 | $67.10 | +165.28% | 20 | Sep 17, 2026 | |
| AKBA Akebia Therapeutics | Reiterated: Buy | $4 | $0.9157 | +336.82% | 15 | Sep 14, 2026 | |
| CGEM Cullinan Therapeutics | Reiterated: Buy | $39 → $40 | $21.08 | +89.75% | 26 | Sep 14, 2026 | |
| CLYM Climb Bio | Reiterated: Buy | $20 → $32 | $14.05 | +127.76% | 11 | Sep 3, 2026 | |
| CNTB Connect Biopharma Holdings | Reiterated: Buy | $10 | $1.28 | +681.25% | 8 | Aug 27, 2026 | |
| SYRE Spyre Therapeutics | Rated: Buy | $132 → $121 | $90.25 | +34.07% | 25 | Aug 26, 2026 | |
| TVRD Tvardi Therapeutics | Reiterated: Buy | $5 | $1.63 | +206.75% | 9 | Aug 19, 2026 | |
| OTLK Outlook Therapeutics | Reiterated: Buy | $4 | $0.6526 | +512.93% | 22 | Aug 14, 2026 | |
| LQDA Liquidia | Reiterated: Buy | $109 → $111 | $66.88 | +65.97% | 47 | Aug 12, 2026 | |
| MAZE Maze Therapeutics | Reiterated: Buy | $46 | $22.52 | +104.26% | 7 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $74 → $77 | $16.94 | +354.55% | 19 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $12.39 | +142.13% | 33 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $151 | $94.96 | +59.01% | 13 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $58 | $16.57 | +250.03% | 11 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $44 | $8.03 | +447.95% | 11 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 | $21.14 | +98.68% | 5 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $58 | $29.41 | +97.21% | 8 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $150 → $175 | $105.04 | +66.60% | 15 | Jun 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $17.02 | - | 16 | Jun 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 → $6 | $3.84 | +56.25% | 16 | Jun 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1 | $0.303 | +230.03% | 14 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $494.63 | - | 19 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $3.42 | +397.08% | 8 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $61 | $22.00 | +177.27% | 20 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $82 | $143.00 | -42.66% | 32 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $0.862 | n/a | 11 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $11.19 | n/a | 18 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $55.20 | n/a | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $8 | $5.50 | n/a | 16 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $6.44 | n/a | 13 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $150 → $50 | $0.1604 | n/a | 5 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4 | $0.22 | n/a | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $28.99 | n/a | 3 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 | $1.36 | n/a | 2 | Apr 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $1.11 | n/a | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $60 | $4.20 | n/a | 1 | Dec 9, 2020 |
Nektar Therapeutics
Sep 17, 2026
Reiterated: Buy
Price Target: $178
Current: $67.10
Upside: +165.28%
Akebia Therapeutics
Sep 14, 2026
Reiterated: Buy
Price Target: $4
Current: $0.9157
Upside: +336.82%
Cullinan Therapeutics
Sep 14, 2026
Reiterated: Buy
Price Target: $39 → $40
Current: $21.08
Upside: +89.75%
Climb Bio
Sep 3, 2026
Reiterated: Buy
Price Target: $20 → $32
Current: $14.05
Upside: +127.76%
Connect Biopharma Holdings
Aug 27, 2026
Reiterated: Buy
Price Target: $10
Current: $1.28
Upside: +681.25%
Spyre Therapeutics
Aug 26, 2026
Rated: Buy
Price Target: $132 → $121
Current: $90.25
Upside: +34.07%
Tvardi Therapeutics
Aug 19, 2026
Reiterated: Buy
Price Target: $5
Current: $1.63
Upside: +206.75%
Outlook Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $4
Current: $0.6526
Upside: +512.93%
Liquidia
Aug 12, 2026
Reiterated: Buy
Price Target: $109 → $111
Current: $66.88
Upside: +65.97%
Maze Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $46
Current: $22.52
Upside: +104.26%
Aug 10, 2026
Reiterated: Buy
Price Target: $74 → $77
Current: $16.94
Upside: +354.55%
Aug 10, 2026
Reiterated: Buy
Price Target: $30
Current: $12.39
Upside: +142.13%
Aug 10, 2026
Reiterated: Buy
Price Target: $151
Current: $94.96
Upside: +59.01%
Aug 6, 2026
Reiterated: Buy
Price Target: $58
Current: $16.57
Upside: +250.03%
Aug 6, 2026
Reiterated: Buy
Price Target: $44
Current: $8.03
Upside: +447.95%
Aug 5, 2026
Reiterated: Buy
Price Target: $42
Current: $21.14
Upside: +98.68%
Aug 3, 2026
Initiated Coverage: Buy
Price Target: $58
Current: $29.41
Upside: +97.21%
Jun 30, 2026
Rated: Buy
Price Target: $150 → $175
Current: $105.04
Upside: +66.60%
Jun 29, 2026
Downgraded: Hold
Price Target: n/a
Current: $17.02
Upside: -
Jun 2, 2026
Reiterated: Buy
Price Target: $5 → $6
Current: $3.84
Upside: +56.25%
Mar 19, 2026
Reiterated: Buy
Price Target: $1
Current: $0.303
Upside: +230.03%
Feb 25, 2026
Reiterated: Hold
Price Target: n/a
Current: $494.63
Upside: -
Feb 20, 2026
Reiterated: Buy
Price Target: $17
Current: $3.42
Upside: +397.08%
Nov 4, 2025
Reiterated: Buy
Price Target: $61
Current: $22.00
Upside: +177.27%
Nov 3, 2025
Reiterated: Buy
Price Target: $82
Current: $143.00
Upside: -42.66%
Mar 31, 2025
Reiterated: Buy
Price Target: $14
Current: $0.862
Upside: n/a
Dec 12, 2024
Downgraded: Hold
Price Target: n/a
Current: $11.19
Upside: n/a
Dec 2, 2024
Downgraded: Hold
Price Target: n/a
Current: $55.20
Upside: n/a
Nov 18, 2024
Upgraded: Buy
Price Target: $8
Current: $5.50
Upside: n/a
Nov 13, 2024
Reiterated: Buy
Price Target: $24
Current: $6.44
Upside: n/a
Nov 9, 2023
Rated: Buy
Price Target: $150 → $50
Current: $0.1604
Upside: n/a
May 3, 2022
Initiated Coverage: Buy
Price Target: $4
Current: $0.22
Upside: n/a
Apr 28, 2021
Reiterated: Buy
Price Target: $12
Current: $28.99
Upside: n/a
Apr 27, 2021
Reiterated: Buy
Price Target: $29
Current: $1.36
Upside: n/a
Apr 20, 2021
Initiated Coverage: Buy
Price Target: $51
Current: $1.11
Upside: n/a
Dec 9, 2020
Initiated Coverage: Buy
Price Target: $60
Current: $4.20
Upside: n/a